© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
December 21, 2010
Targeting chemotherapy with 70-gene MammaPrint signature in patients 60 years or younger with node-negative breast cancer is likely to be cost-effective.